4.8 Article

Tristetraprolin Impairs Myc-Induced Lymphoma and Abolishes the Malignant State

Journal

CELL
Volume 150, Issue 3, Pages 563-574

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2012.06.033

Keywords

-

Funding

  1. NIH [DK44158, CA167093, F32-CA115075, CA134609]
  2. ThinkPink Kids Foundation
  3. State of Florida
  4. NIH, NIEHS
  5. National City Postdoctoral Fellowship
  6. Glenn W. Bailey Postdoctoral Fellowship
  7. PGA National Women's Cancer Foundation

Ask authors/readers for more resources

Myc oncoproteins directly regulate transcription by binding to target genes, yet this only explains a fraction of the genes affected by Myc. mRNA turnover is controlled via AU-binding proteins (AUBPs) that recognize AU-rich elements (AREs) found within many transcripts. Analyses of precancerous and malignant Myc-expressing B cells revealed that Myc regulates hundreds of ARE-containing (ARED) genes and select AUBPs. Notably, Myc directly suppresses transcription of Tristetraprolin (TTP/ZFP36), an mRNA-destabilizing AUBP, and this circuit is also operational during B lymphopoiesis and IL7 signaling. Importantly, TTP suppression is a hallmark of cancers with MYC involvement, and restoring TTP impairs Myc-induced lymphomagenesis and abolishes maintenance of the malignant state. Further, there is a selection for TTP loss in malignancy; thus, TTP functions as a tumor suppressor. Finally, Myc/TTP-directed control of select cancer-associated ARED genes is disabled during lymphomagenesis. Thus, Myc targets AUBPs to regulate ARED genes that control tumorigenesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available